Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Boehringer Ingelheim
Harvard Business School
Baxter
Colorcon

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 7,196,054

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 7,196,054
Title:Methods for treating wound tissue and forming a supplemented fibrin matrix
Abstract: This invention provides supplemented and unsupplemented tissue sealants as well as methods for their production and use thereof. Disclosed are tissue sealants supplemented with at least one antimicrobial composition. The composition may be further supplemented with, for example, one or more antibodies, analgesics, anticoagulants, antiproliferatives, anti-inflammatory compounds, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like.
Inventor(s): Drohan; William N. (Springfield, VA), MacPhee; Martin J. (Darnestown, MD), Nunez; Hernan (Derwood, MD), Liau; Gene (Wayland, MA), Maciag; Thomas (Portland, ME), Burgess; Wilson H. (Clifton, VA)
Assignee: The American National Red Cross (Rockville, MD)
Application Number:08/485,883
Patent Claims:1. A method for treating wounded tissue in a patient, comprising applying to the wounded tissue a composition in the form of a dry powder comprising fibrinogen in an amount which forms a fibrin matrix in the presence of thrombin, Factor XIII, Ca.sup.++, and aqueous solution; providing to the composition, thrombin, Factor XIII, Ca.sup.++ and aqueous solution in amounts which form a fibrin matrix in the presence of fibrinogen; wherein said aqueous solution is provided to the dry powder composition at the site of the wounded tissue; further wherein said composition is free of collagen; further wherein said composition contains no added fibrinolysis inhibitor; and further forming a fibrin matrix when said fibrinogen is applied to said wounded tissue in the presence of thrombin, Factor XIII, and Ca.sup.++, said fibrin matrix covering and adhering to said wounded tissue.

2. The method of claim 1, wherein said composition further comprises at least one component selected from the group consisting of Factor XIII, thrombin or other catalyst of fibrin formation, and Ca.sup.++.

3. The method of claim 1, wherein said composition further comprises at least two components selected from the group consisting of Factor XIII, thrombin or other catalyst of fibrin formation, and Ca.sup.++.

4. The method of claim 1, wherein said composition further comprises Factor XIII, thrombin or other catalyst of fibrin formation, and Ca.sup.++.

5. The method of claim 1, wherein said composition further comprises at least one supplement selected from the group consisting of: analgesics, anesthetics, antimicrobial compounds, antibodies, anticoagulants, anti-inflammatory compounds, antiproliferatives, cytokines, cytotoxins, chemotherapeutic drugs, growth factors, hormones, interferons, lipids or lipid-containing structures, polynucleotides or oligonucleotides, osteoinducers, polymers, polysaccharides, proteoglycans, polypeptides, protease inhibitors, steroids, vasoconstrictors, vasodilators, vitamins, nutritional minerals and stabilizers.

6. The method of claim 5, wherein said supplement is at least one antibody and/or at least one antimicrobial compound.

7. The method of claim 5, wherein said supplement is at least one growth factor.

8. The method of claim 7, wherein said growth factor is selected from the group consisting of: fibroblast growth factors; platelet-derived growth factors; insulin-like growth factors; epidermal growth factors; transforming growth factors; cartilage-inducing factors; osteoid-inducing factors; osteogenin and other bone growth factors; heparin-binding growth factors; cytokines; interferons; and vascular endothelial growth factors.

9. The method of claim 7, wherein the composition further comprises at least one antibody and/or antimicrobial compound.

10. The method of claim 7, wherein the composition further comprises at least one cytotoxin or cell proliferation inhibiting compound.

11. The method of claim 5, wherein said supplement is at least one cytotoxin or cell proliferation inhibiting compound.

12. The method of claim 11, wherein said cytotoxin or cell proliferation inhibiting compound is selected from the group consisting of enzyme inhibitors, proliferation inhibitors, and dichloroethylsulfide derivatives.

13. The method of claim 11, wherein said cytotoxin or cell proliferation inhibiting compound is selected from the group consisting of 5-fluorouracil, azaribine, estrogen, hormone analogs, insulins, hydoxyurea, L-asparaginase, prednisilone, prednisone, steroids, testosterone, vinblastine, vincristine, taxol, taxotere, gentamycin, carboplatin, cyclophosphamide, and venoms.

14. The method of claim 11, wherein said composition further comprises at least one antibody and/or antimicrobial compound.

15. The method of claim 5, wherein said supplement is released from said fibrin matrix upon dissolution of the fibrin clot for a sustained period, wherein said sustained period is greater than the period obtained according to simple diffusion kinetics.

16. The method of claim 15, wherein said supplement interacts with said fibrin matrix so as to increase the longevity and/or stability of said fibrin matrix compared to that of an unsupplemented fibrin matrix.

17. The method of claim 15, wherein said supplement is of sufficiently low solubility to permit localized, sustained-release of said supplement from said fibrin matrix, wherein said sustained period is greater than the period obtained according to simple diffusion kinetics.

18. The method of claim 1, wherein said composition further comprises at least one supplement selected from the group consisting of fibrin, gelatin, silk proteins and derivatives of fibrin, gelatin, and silk proteins.

19. A method for forming a supplemented fibrin matrix, the method comprising applying to wounded tissue a composition in the form of a dry powder comprising fibrinogen in an amount which forms a fibrin matrix in the presence of thrombin, Factor XIII, and Ca.sup.++, providing to the composition, thrombin, Factor XIII, Ca.sup.++ and aqueous solution in amounts which form a fibrin matrix in the presence of fibrinogen, wherein said aqueous solution is provided to the dry powder composition at the site of the wounded tissue, wherein said composition is free of collagen; further wherein said composition contains no added fibrinolysis inhibitor, further wherein the composition further comprises at least one supplement selected from the group consisting of: analgesics, anesthetics, antimicrobial compounds, antibodies, anticoagulants, anti-inflammatory compounds, antiproliferatives, cytokines, cytotoxins, chemotherapeutic drugs, growth factors, hormones, interferons, lipids or lipid-containing structures, polynucleotides or oligonucleotides, osteoinducers, polymers, polysaccharides, proteoglycans, polypeptides, protease inhibitors, steroids, vasoconstrictors, vasodilators, vitamins, nutritional minerals and stabilizers; and further forming a fibrin matrix when said fibrinogen is applied to said wounded tissue in the presence of thrombin, Factor XIII, and Ca.sup.++, said fibrin matrix covering and adhering to said wounded tissue.

20. The method of claim 5, wherein said supplement is an anesthetic.

21. The method of claim 5, wherein said supplement is an anesthetic and an antimicrobial compound.

22. The method of claim 1, wherein said fibrinogen is recombinantly-produced human fibrinogen.

23. The method of any one of claims 2 4, wherein said thrombin is recombinantly-produced human thrombin.

24. The method of any one of claims 2 4, wherein said Factor XIII is recombinantly-produced human Factor XIII.

25. The method of claim 8, wherein said growth factor is selected from the group consisting of: fibroblast growth factor-1, fibroblast growth factor-2 and fibroblast growth factor-4; platelet-derived growth factor; insulin-like growth factor-1, insulin-like growth factor-2; epidermal growth factor; transforming growth factor-.beta.; transforming growth factor-.beta.; cartilage-inducing factor-A, cartilage-inducing factor-B; osteoid-inducing factor; osteogenin; heparin-binding growth factor-1 and heparin-binding growth factor-2.

26. The method of claim 1, wherein said composition further comprises a physiologically acceptable propellant.

27. The method of claim 26, wherein said propellant is selected from the group consisting of carbon dioxide, nitrogen, chlorofluorocarbons and hydrofluorocarbons.

28. The method of claim 5, 7, 9 or 10, wherein said composition further comprises at least one regulatory compound selected from the group consisting of inhibiting compounds and potentiating compounds, wherein said inhibiting compounds inhibit agents that interfere with the ability of said growth factor to regulate or mediate cell proliferation, cell differentiation, tissue regeneration, cell attraction, wound repair and/or any cell developmental or proliferative process, while said potentiating compounds increase and/or mediate the ability of said growth factor to regulate or mediate cell proliferation, cell differentiation, tissue regeneration, cell attraction, wound repair and/or any cell developmental or proliferative process.

29. The method of claim 28, wherein said regulatory compound increases and/or mediates the ability of said growth factor supplement to regulate or mediate cell proliferation, cell differentiation, tissue regeneration, cell attraction, wound repair and/or any cell developmental or proliferative process while also inhibiting agents that interfere with the ability of said growth factor to regulate or mediate cell proliferation, cell differentiation, tissue regeneration, cell attraction, wound repair and/or any cell developmental or proliferative process.

30. The method of claim 28, wherein said regulatory compound is heparin.

31. The method of claim 1, wherein said composition further comprises at least one pharmaceutically acceptable diluent, filler or excipient.

32. The method of claim 31, wherein said at least one pharmaceutically acceptable diluent, filler or excipient increases the solubility of said fibrin sealant composition.

33. The method of claim 1, wherein the composition further comprises at least one antioxidant.

34. The method of claim 26, wherein said physiologically acceptable propellant has a boiling point below physiological temperature.

35. The method of claim 32, wherein said pharmaceutically acceptable diluent, filler or excipient is sucrose.

36. The method of claim 29, wherein said regulatory compound is heparin.

37. A method for forming a fibrin matrix, said method comprising applying to wounded tissue a composition in the form of a dry powder comprising fibrinogen in an amount which forms a fibrin matrix in the presence of thrombin and Ca.sup.++ and aqueous solution; providing to the composition thrombin, Ca.sup.++ and aqueous solution in amounts which form a fibrin matrix in the presence of fibrinogen; wherein said composition is free of collagen; wherein said aqueous solution is provided to the dry powder composition at the site of the wounded tissue; and further wherein said composition contains no added fibrinolysis inhibitor.

38. A method for forming a supplemented fibrin matrix, said method comprising applying to wounded tissue a composition in the form of a dry powder comprising an effective amount of at least one supplement and fibrinogen in an amount which forms a fibrin matrix in the presence of thrombin, Factor XIII, Ca.sup.++ and aqueous solution; and providing to the composition thrombin, Factor XIII, Ca.sup.++ and aqueous solution in amounts which form a fibrin matrix in the presence of fibrinogen; wherein said aqueous solution is provided to the dry powder composition at the site of the wounded tissue; wherein said composition is free of collagen; wherein said composition contains no added fibrinolysis inhibitor; and wherein said supplement is releasable from said fibrin matrix upon dissolution of the clot into the external environment of use for a sustained period, further wherein the amount of said supplement in said composition is greater than the amount of said supplement which is soluble in the fibrin matrix, and further wherein said sustained period is greater than the period obtained according to simple diffusion kinetics.

39. The method of claim 38, wherein said supplement is selected from the group consisting of: analgesics, an anesthetic, an antibiotic, an antimicrobial compound, an antiangiogenin, an anticoagulant, an antifibrinolytic agent, an antifungal agent, an anti-inflammatory compound, an antiseptic compound, an antiparasitic agent, an antiviral compound, a cardiovascular drug, a cytotoxin or cell proliferation inhibiting compound, a chemotherapeutic drug, a lipid or liposome, an osteogenic compound, a cartilage inducing compound, a protease inhibitor, a steroid, a vasoconstrictor, a vasodilator, a vitamin, a nutritional supplement, and a mineral.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
McKinsey
Express Scripts
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.